



1626

CASE CT-2645 NP

**CERTIFICATE OF MAILING**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Samuel J. DuBoff  
Type or print name

*Samuel J. DuBoff*  
Signature

January 28, 2003  
Date

RECEIVED  
FEB 06 2003  
TECH CENTER 1600/2900

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF  
YU ET AL.

EXAMINER: REBECCA L. ANDERSON  
ART UNIT: 1626

APPLICATION NO: 09/994,012

FILED: NOVEMBER 16, 2001

FOR: HETEROCYCLIC SUBSTITUTED 2-METHYL-BENZIMIDAZOLE  
ANTIVIRAL AGENTS

Assistant Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In follow-up to your telephone call of January 28, 2003, I am faxing to you as requested replacement copies of references AT, AZ, AX, BA and BB (copy of IDS Form PTO-1449 attached for ease of reference) which were previously submitted February 7, 2002. A hard copy of these references will also be mailed to you.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,


Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(203) 677-7787

*Samuel J. DuBoff*  
Samuel J. DuBoff  
Attorney for Applicants  
Reg. No. 25,969

Date: 1/28/03

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
CT-2645 NP  
APPLICATION NO.  
09/994,012  
APPLICANT  
YU ET AL.  
FILING DATE  
November 16, 2001

Sheet 1 of 2

RECEIVED  
FEB 06 2003  
TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	4,324,794	4/13/82	R. R. Tidwell, et al			
	AB	5,256,668	10/26/93	K.-H. L. Hsu, et al			
	AC	3,394,141	7/23/68	F. Sparatore			
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AJ	EP 058146A1	8/18/82	US Patent 4,525,358 English <i>Equivalent</i>			<input type="checkbox"/>	<input type="checkbox"/>
	AK	AU-A-14,704	12/22/98	US Patent 5,852,015 English <i>Equivalent</i>			<input type="checkbox"/>	<input type="checkbox"/>
	AL	WO 01/36395	5/25/01	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AM	WO 00/38508	7/6/00	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 01/00611	1/4/01	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 01/00612	1/4/01	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AP	WO 01/00615	1/4/01	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	WO 00/04900	2/3/00	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	E. J. Dubovi, et al, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 19(4), pp. 649-656, 1981
AS	P. R. Wyde, et al, ANTIVIRAL RESEARCH, 38, pp. 31-42, 1998
AT	F. Pagani, et al, BOLL. CHIM. FARM., 104, pp. 427-431, 1965

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

*(Use several sheets if necessary)*

ATTY. DOCKET NO.  
CT-2645 NP  
APPLICATION NO.  
09/994,012  
APPLICANT  
YU ET AL.  
FILING DATE  
November 16, 2001

Sheet 2 of 2

**RECEIVED**  
FEB 06 2003  
Group  
TECH CENTER 1600/2900

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

AU	G. Paglietti, et al, IL. FARMACO-ED. SC., <b>30</b> , pp. 505-511, 1975
AV	S. Shigeta, et al, ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, <b>3</b> (3), pp. 171-177, 1992
AW	W. R. Roderick, et al, J. MED. CHEM., <b>15</b> (6), pp. 655-658, 1972
AX	B. Cakir, et al, GAZI ECZACILIK FAK. DER., <b>5</b> (1), pp. 71-77, 1988
AY	H. R. Howard, et al, EUR. J. MED. CHEM., <b>27</b> , pp. 779-789, 1992
AZ	F. Sparatore, et al, IL FARMACO ED. SCI., <b>33</b> , pp. 901-923, 1978
BA	JAMA, <b>277</b> (1), pp. 12-13, 1997
BB	E. De Clercq, INT. J. ANTIMICROBIAL AGENTS, <b>7</b> , pp. 193-202, 1996
BC	R. R. Tidwell, et al, J. MED. CHEM., <b>26</b> , pp. 294-298, 1983
BD	
BE	
BF	
BG	
BH	

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

